NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma
Sim H, Wachsmuth L, Barnes E, Yip S, Koh E, Hall M, Jennens R, Ashley D, Verhaak R, Heimberger A, Rosenthal M, Hovey E, Ellingson B, Tognela A, Gan H, Wheeler H, Back M, McDonald K, Long A, Cuff K, Begbie S, Gedye C, Mislang A, Le H, Johnson M, Kong B, Simes J, Lwin Z, Khasraw M. NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neuro-Oncology Advances 2023, 5: vdad124. PMID: 37841696, PMCID: PMC10576515, DOI: 10.1093/noajnl/vdad124.Peer-Reviewed Original ResearchExperimental armStandard armOverall survivalAdverse eventsGrade-3 immune-related adverse eventImmune-related adverse eventsUnexpected serious adverse eventsRandomized phase II studyRandomized phase II trialCombination of nivolumabMedian overall survivalPhase II studySerious adverse eventsNew safety signalsOS hazard ratioPhase II trialPhase III trialsAdjuvant nivolumabImmunologic rationaleII trialHazard ratioII studyIII trialsOlder patientsImmunotherapy trialsLongitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
van Garderen K, Vallentgoed W, Lavrova A, Niers J, de Leng W, Hoogstrate Y, de Heer I, Ylstra B, van Dijk E, Klein S, Draaisma K, Robe P, Verhaak R, Westerman B, French P, van den Bent M, Kouwenhoven M, Kros J, Wesseling P, Smits M. Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort. Neuro-Oncology Advances 2023, 5: vdad149. PMID: 38024241, PMCID: PMC10681663, DOI: 10.1093/noajnl/vdad149.Peer-Reviewed Original ResearchIDH-mutant astrocytomasFluid attenuated inversion recoveryT2-FLAIR mismatchOverall survivalSecond resectionMicrocystic changesT2-FLAIR mismatch signTumor tissueMedian overall survivalGrade 2 tumorsMagnetic resonance imagingSpecific diagnostic markerSurgical resectionFavorable prognosisRecurrent tumorsClinical parametersPrognostic valueFirst resectionHyperintense areasTumor gradeResectionGrade 2AstrocytomasResonance imagingDiagnostic marker